LYSGF News and Press, Lysogene

Regulatory News: Lysogene (FR0013233475 – LYS) (Paris:LYS), a phase 3 gene therapy platform Company targeting central nervous system (CNS) diseases, announces that, upon decision of the judicial administrator, the deadline for submitting offers has been extended from February 15, 2023 ...

Regulatory News: Lysogene (FR0013233475 – LYS) (Paris:LYS), a phase 3 gene therapy platform Company targeting central nervous system (CNS) diseases, announces the conversion of the safeguard proceedings which has been in place since December 13, 2022 into reorganization proceedings. ...

Regulatory News: Lysogene (FR0013233475 – LYS) (Paris:LYS), a phase 3 gene therapy platform Company targeting central nervous system (CNS) diseases, announces that it has requested, jointly with the judicial administrator, the conversion of safeguard proceedings, opened on December 13,...

In the cohort of patients enrolled before the age of 30 months, a statistically significant improvement in cognitive development (assessed by BSID-III, Bayley’s Scales of Infant Development, third edition) compared to natural history data was observed. Key secondary efficac...

Lysogene S.A. press release ( OTC:LYSGF ): 1H GAAP EPS of €0.04. Revenue of €8.44M (+189.0% Y/Y). Cash position of €7.7M at the end of June 2022, providing financial visibility to the end of January 2023. For further details see: Ly...

Lysogene S.A. press release (OTCPK:LYSGF): FY GAAP EPS of -€0.81. Revenue of €3.73M (-72.1% Y/Y). For further details see: Lysogene S.A. GAAP EPS of -€0.81, revenue of €3.73M

SIOX presented excellent data in its higher dose GM1 Gangliosidosis gene therapy program. Unfortunately, after hours that same day, its chief research and development officer announced he was moving on to another company. Investors seem to have latched on the latter news rather th...

Lysogene S.A. (LYSGF): FY GAAP EPS of -€0.32.Revenue of €13.37M (flat Y/Y)Press Release For further details see: Lysogene S.A. reports FY results

Baird has issued Sarepta Therapeutics (SRPT) an Outperform rating citing the positive topline data from the Phase 3 study conducted in partnership with Lysogene (LYSGF) for LYS-SAF302. The price target of $192 implies an 11.7% upside to today’s close.In the ongoing phase 2/3 clinical t...

LYSOGENE SA ( OTCPK:LYSGF ): FY Net loss of €4.28M. More news on: LYSOGENE SA, Earnings news and commentary, , Read more ...